Efficient delivery of anti-miR-210 using Tachyplesin, a cell penetrating peptide, for glioblastoma treatment
Graphical abstract
Introduction
Glioblastoma (GBM) is the most malignant grade IV tumor of the central nervous system (Parsons et al., 2008). It is a fatal brain tumor with an annual incidence of 5 in 100,000 people (Omuro and DeAngelis, 2013). The current treatment modality involves surgical resection along with radiation therapy and rounds of temozolomide (TMZ)-chemotherapy, however the outcome remains extremely poor, with the median survival period of around 15 months (Combs et al., 2011). A very aggressive growth rate, diffused boundaries, invasive behaviour and development of drug resistance make it even more resistant to the available therapies (Zhu et al., 2009).
Recent studies suggest microRNA (miRNA) based therapies as a promising option for GBM treatment. miRNAs are small non-coding RNAs that interact with a wide range of target transcripts most commonly at the 3′ UTR region and bring about their degradation or translational repression (Wu et al., 2019, Nikaki et al., 2012). Aberrant levels of miRNAs have been reported in various pathological conditions including cancer. Specific miRNAs have been shown to play an oncogenic or tumor suppressive role in various cancers (Reddy, 2015). It is widely agreed that downregulation of oncogenic miRNAs or upregulation of tumor suppressor miRNAs has immense potential for cancer treatment. miRNAs may provide more comprehensive benefits than other targets with limited activities since one miRNA can control the expression of wide range of targets and thus oncogenic pathways (Lawler and Chiocca, 2009). While the potential of miRNAs as therapeutic targets is indeed exciting, the delivery of miRNAs remain major obstacle due to their charge and biological instability (Mondal et al., 2019, Chen et al., 2015, Kwekkeboom et al., 2014). Therefore, search for a safe, highly effective delivery system for miRNA-based therapy continues.
Antimicrobial peptides (AMPs) have a broad spectrum action against gram positive and gram negative bacteria, viruses, fungi and parasites (Lakshmaiah Narayana and Chen, 2015). Recently a number of reports have shown that cationic antimicrobial peptides exhibit potent cytotoxicity towards cancer cells without harming normal cells (Smolarczyk et al., 2009, Liu et al., 2015). This selectivity of peptides towards cancer cells is mainly due to the presence of negatively charged cancer cell membrane leading to electrostatic interaction between cationic antimicrobial peptide and cancer cells (Smolarczyk et al., 2009, Gaspar et al., 2013). AMPs mainly act by membranolytic mechanism leading to membrane destabilization and cell lysis (Fadnes et al., 2009). Therefore, it is possible that the cell penetrating antimicrobial peptides with an efficient cellular uptake by cancer cells may result in efficient and selective delivery of anti-cancer therapeutics in different cancer types. In our previous reports we have successfully shown that marine AMP, Tpl, derived from horseshoe crab can act as a cell penetrating peptide (CPP) with efficient cargo delivery ability (Jain et al., 2015). Thus, employing CPPs for miRNA delivery in cancer cells seems to be a promising new approach. The cationic nature of the CPPs allows them to electrostatically bind to the phosphate backbone of nucleic acids to form a stable complex and protect the nucleic acid from degradation (Suh et al., 2013).
CPPs have the ability to cross the cell membrane and can increase transport efficiency of different cargo molecules across the blood brain barrier (BBB). Though quantitative studies are still lacking. The ability of CPPs to pass through BBB is dependent on various aspects like multiple time regression (MTR), unidirectional influx rate, brain to serum activity etc. MTR analysis of different peptides disclose divergent influx through BBB, though influx properties cannot be correlated with their cell penetrating ability. That may be because of differences in cellular influx mechanism and secondary structures (Stalmans et al., 2015).
There are many reports claiming the blood brain permeability of Tpl. The work has demonstrated that Tpl, Protegrin or peptides derived from them act as excellent delivery vehicles for transfer of various cargoes across BBB (Mouchet et al., 2003).
Our study mainly focuses on developing a peptide based nanocarrier system for the delivery of anti-miRNAs for inhibiting oncogenic miRNAs. We specially aim to target an established oncogenic miRNA- miR210 which is known to be highly expressed in various cancers such as breast cancer, prostate cancer and GBM (Giannakakis et al., 2008, Grosso et al., 2013, Gee et al., 2010). We have recently shown high levels of miR210 in GBM patients as compared to normal brain cells in both TCGA-GBM patient dataset and Indian GBM patients (Agrawal et al., 2014, Agrawal et al., 2018, Lai et al., 2015). miR210 levels increase with tumor grade and has been correlated with poor prognosis of GBM patients. miR210 plays an oncogenic role in GBM by promoting cell proliferation, migration, invasion, and inhibition of apoptosis (Agrawal et al., 2014, Agrawal et al., 2018).
Here, we have screened a number of CPPs which includes, Tat2 which is TAT dimer (Jain et al., 2015) and random coil in nature, Tpl, derived from marine origin which is cationic and β hairpin peptide (Nakamura et al., 1988) and CyLoP-1 (Ponnappan et al., 2017) snake toxin derived and is random coil in nature, LN and LDP which are α-helical in nature and are spider toxin derived (Ponnappan and Chugh, 2017), for their membrane translocation abilities in GBM cells. Our work demonstrates that Tpl, a known antimicrobial peptide, shows excellent cell penetrating ability in GBM cells and is also known to effectively cross BBB (Mouchet et al., 2003). Further, we show that Tpl forms a complex with anti-miRNA and delivers it efficiently into GBM cells with higher transfection efficiency compared to lipofectamine reagent. Further, anti-miR210:Tpl complex brings about a significant reduction in miR210 levels with a concomitant increase in the levels of its target genes. We also show that treatment of GBM cells with anti-miR210:Tpl complex brings about significant inhibition of cell proliferation, spheroid formation, migration and induces apoptosis in GBM cells. Further, anti-miR210:Tpl complex also sensitizes GBM cells to chemodrug, TMZ, treatment. Our findings demonstrate that efficient delivery of anti-miR210 molecule with CPP may hold great promise for treatment of GBM and other solid tumours with high miR210 levels.
Section snippets
Materials
Peptides used in the study were custom synthesized as non–labelled or FITC labelled at N-terminus with more than 95% purity by solid phase peptide synthesis from GenPro Biotech, New Delhi, India.
Cell culture
The human GBM cell line U87MG was obtained from the National Centre for Cell Sciences, Pune, while T98G cell lines were a kind gift from Dr. Ellora Sen, NBRC, Manesar. The cell lines were grown in Dulbecco’s modified Eagle’s medium (DMEM, Thermo Fisher,Gibco). The medium was supplemented with 10% Fetal
Screening of cell penetrating peptides based upon their uptake in GBM cell lines
Five FITC labelled CPPs, Tat2, CyloP-1, Tpl, LDP and LN at varying concentrations (5, 10, 15 and 20 μM) were screened for their cellular uptake in T98G, for an incubation period of 1 h and 2 h (CyLoP-1). From the qualitative data we observed that among all the peptides assessed, Tpl exhibited maximal uptake at a concentration of 5 μM (Fig. 1A–E). Mutated Tpl where arginine is replaced by alanine exhibited no cellular uptake, thereby serving as a negative control for the study.
However, from the
Discussion
Cell penetrating antimicrobial peptides have proven to be promising cellular delivery agents without posing any cellular cytotoxicity. They are also known to act as potent nanocarriers for various macromolecules like oligonucleotides, proteins and therapeutic drugs attributing to their small size and cargo delivery ability (Mae and Langel, 2006). The present study demonstrates excellent cell penetrating and miRNA delivery ability of Tpl in GBM cell lines grown in 2D or 3D format. Tpl is a
Conclusions
To summarize we can say that Tpl effectively forms non covalent complex with anti-miR210 and efficiently delivers it inside GBM cells. The complex formed is found to be highly stable in the presence of serum and heparin at the concentrations employed. Once inside the cells, the complex significantly exhibited anti-cancer activity by affecting various hallmarks of cancer namely proliferation, migration, spheroid formation, apoptosis and miR-210 target gene expression. Cells were even found to be
Declaration of Competing Interest
The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Acknowledgements
RK and AC are thankful to IIT Delhi for the award of internal grant (MI01694G, Faculty Interdisciplinary Research Programme) for funding this study. AJ is thankful to Ministry of Human Resource and Development (MHRD), Govt. of India for award of Senior Research Fellowship. PN is thankful to Council of Scientific & Industrial Research, Govt. of India for the award of Senior Research Fellowship.
Funding: RK is also thankful to Department of Biotechnology, Government of India (
References (37)
- et al.
In vivo delivery of miRNAs for cancer therapy: Challenges and strategies
Adv Drug Deliv Rev.
(2015) - et al.
MicroRNA-210 overexpression predicts poorer prognosis in glioma patients
J Clin Neurosci.
(2014) - et al.
Antimicrobial peptides: Possible anti-infective agents
Peptides
(2015) - et al.
Cell-penetrating peptides as vectors for peptide, protein and oligonucleotide delivery
Curr Opin Pharmacol.
(2006) - et al.
Tachyplesin, a class of antimicrobial peptide from the hemocytes of the horseshoe crab (Tachypleus tridentatus). Isolation and chemical structure
J Biol Chem.
(1988) - et al.
Cell-penetrating and cargo-delivery ability of a spider toxin-derived peptide in mammalian cells
Eur J Pharm Biopharm.
(2017) - et al.
CyLoP-1: Membrane-active peptide with cell-penetrating and antimicrobial properties
Biochim Biophys Acta - Biomembr.
(2017) - et al.
Peptide-mediated intracellular delivery of miRNA-29b for osteogenic stem cell differentiation
Biomaterials
(2013) - et al.
An overview of the multifaceted roles of miRNAs in gastric cancer: Spotlight on novel biomarkers and therapeutic targets
Biochem Pharmacol.
(2019) - et al.
Antiviral function of Tachyplesin I against iridovirus and nodavirus
Fish Shellfish Immunol.
(2016)
Arginine-rich, cell penetrating peptide–anti-microRNA complexes decrease glioblastoma migration potential
Peptides
p53 and miR-210 regulated NeuroD2, a neuronal basic helix-loop-helix transcription factor, is downregulated in glioblastoma patients and functions as a tumor suppressor under hypoxic microenvironment
Int J Cancer.
Prognostic significance of IDH-1 and MGMT in patients with glioblastoma: One step forward, and one step back?
Radiat Oncol.
Effects of tachyplesin I on human U251 glioma stem cells
Mol Med Rep.
The anticancer activity of lytic peptides is inhibited by heparan sulfate on the surface of the tumor cells
BMC Cancer.
From antimicrobial to anticancer peptides
A review. Front Microbiol.
Hsa-miR-210 is a marker of tumor hypoxia and a prognostic factor in head and neck cancer
Cancer
Cited by (26)
Engineered smart materials for RNA based molecular therapy to treat Glioblastoma
2024, Bioactive MaterialsMethods of miRNA delivery and possibilities of their application in neuro-oncology
2023, Non-coding RNA ResearchInsight on the hub gene associated signatures and potential therapeutic agents in epilepsy and glioma
2023, Brain Research BulletinMicroRNA-based therapy for glioblastoma: Opportunities and challenges
2023, European Journal of PharmacologyCitation Excerpt :Research on curcumin, another potential therapeutic drug, showed that upregulating the expression of miR-378 reinforced the effect of curcumin on suppressing the proliferation of U87 cells mainly by altering p38 gene expression in vitro and in vivo (Li et al., 2015, 2017). Jana et al. explored a novel role for tachyplesin (Tpl), a cell-penetrating antimicrobial peptide that plays an adjuvant role in facilitating the delivery of drugs into glioma cells to inhibit the expression of miR-210, proliferation, migration and spheroid formation ability by upregulating the expression of its targeted tumor suppressor genes NEUROD2 and HIF-3α and inducing apoptosis by increasing the levels of caspase 3/7 (CASP3/7) and ROS (Jana et al., 2019). Tumor necrosis factor-related apoptosis-inductive ligand (TRAIL) is a novel drug target for cancer therapy that has entered clinical trials (phases II and III) (Davies, 2014).
MicroRNA delivery systems in glioma therapy and perspectives: A systematic review
2022, Journal of Controlled ReleaseCitation Excerpt :We identified a total of 599 articles, and of these, 40 articles were selected and included in the present study (Fig. 1). We included experimental pre-clinical studies, of which 33were performed with miRNA elements coupled with supramolecular systems. [24–63]. As mentioned, some miRNAs might induce cellular changes, such as unrestrained division, angiogenesis, and apoptosis evasion, which can lead to tumorigenic events in patients with glioma. [64]
- 1
Equal contributing First Authors.